Tremfya demonstrated greater treatment persistence than interleukin-17 inhibitors in patients with moderate to severe plaque psoriasis and achieved clinical efficacy in scalp psoriasis. The pairwise analyses of this drug among bio-naïve and bio-experienced patients, in addition to a study looking at the drug’s efficacy in scalp psoriasis, were presented at the American Academy of Dermatology Annual Meeting. Tremfya (guselkumab, Janssen Biotech) is the first and only fully human selective interleukin (IL)-23 approved in the United States for adults with moderate to severe plaque psoriasis. Tremfya demonstrated greater treatment persistence than interleukin-17 inhibitors in patients with moderate to severe plaque psoriasis and achieved clinical efficacy in scalp psoriasis, according to data presented here.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |